Anika Therapeutics, Inc. · Brief

Next report

4 days

Nov 4 · before openest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

3 of 8≥ implied

Mar 12 '25±9.7%▼−11.10%×1.14

May 9 '25±25.9%▼−21.03%×0.81

Jul 30 '25±22.2%▼−27.42%×1.23

Nov 5 '25±36.0%▲+2.28%×0.06

Jan 8 '26±47.6%▼−0.31%×0.01

Feb 26 '26±26.8%▲+16.91%×0.63

Q1 FY26±10.9%▼−18.81%×1.72

Q2 FY26±24.0%▲+6.73%×0.28

quarterimplied−50%0+50%realized×

Q2 FY26±24.0%▲+6.73%×0.28

Q1 FY26±10.9%▼−18.81%×1.72

Feb '26±26.8%▲+16.91%×0.63

Jan '26±47.6%▼−0.31%×0.01

Nov '25±36.0%▲+2.28%×0.06

Jul '25±22.2%▼−27.42%×1.23

2 older reports

May '25±25.9%▼−21.03%×0.81

Mar '25±9.7%▼−11.10%×1.14

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 4 report · est.

Bull1

132managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 4

50.00%revenue from the largest disclosed customer Johnson & Johnson MedTechSEC filings

3tracked funds holding ANIKN-PORT · Aug 31 '26

AI captions · Sep 27 '26once per report · top 2 per case

ANIK report session

No linked exposure.

Oct 21impliedImplied move: ±20.4% into Nov 4 earnings (Oct 21 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.